B+
Bull case
20%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
CLRB
Cellectar BiosciencesANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is supported by reported CLOVER-WaM results in a post-BTK-inhibitor subset: 100% clinical benefit rate, 87.5% overall response rate, 79.2% major response rate, and 16-month median duration of response. Phase 3 site activation and the planned mid-2027 NDA provide a credible regulatory path [#SEC-8K-2026-08-13].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Confirmatory Phase 3 enrollment, timing, and clinical-outcome risk.
Momentum
69
Value
58
Sentiment
74
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.50 · Bull $5.00 · Bear $1.20Analysis 2026-08-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $11.50
Why
Momentum69 · Δ7d -
Value58 · Δ7d 0.0
Sentiment74 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Confirmatory Phase 3 enrollment, timing, and clinical-outcome risk.
- • FDA or other regulatory delays could defer or prevent the planned accelerated-approval filing.
- • The bear case is that positive early-stage data do not translate into successful randomized-study execution, approval, or commercialization.
Catalyst clock
2026-11-23
Confirmatory Phase 3 site activation and early-2027 dosing
Lead driver: Sentiment · See AI snapshot
Momentum
69
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+17.0
Sentiment
74
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 69.2 / Value 58.1 / Sentiment 74.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-25. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$24.2M
Beta
0.30
Shares Out
7.99M
P/E (TTM) · Derived
-0.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.75
Rev YoY
-
EPS YoY
-83.3%
Gross Margin
-
Op Margin
-
Net Debt
-$12.79M
Current Ratio
6.66
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data